Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Len Verbeke

Showing results (11-20 of 22) with videos related to

Pageof 3
Sort By:
Expert Review of Gastroenterology & Hepatology|July 26, 2011
Acute-on-chronic liver failure: current concepts on definition, pathogenesis, clinical manifestations and potential therapeutic interventionsWim Laleman, Len Verbeke, Philippe Meersseman, et al.
Endoscopy|November 25, 2017
The economic impact of using single-operator cholangioscopy for the treatment of difficult bile duct stones and diagnosis of indeterminate bile duct stricturesPierre H Deprez, Rodrigo Garces Duran, Tom Moreels, et al.
Hepatology (Baltimore, Md.)|November 22, 2013
Obeticholic acid, a farnesoid X receptor agonist, improves portal hypertension by two distinct pathways in cirrhotic ratsLen Verbeke, Ricard Farre, Jonel Trebicka, et al.
Plos One|January 7, 2017
Farnesoid X Receptor Activation Attenuates Intestinal Ischemia Reperfusion Injury in RatsLaurens J Ceulemans, Len Verbeke, Jean-Paul Decuypere, et al.
Transplantation Direct|April 18, 2019
Age Matching of Elderly Liver Grafts With Elderly Recipients Does Not Have a Synergistic Effect on Long-term Outcomes When Both Are Carefully SelectedNicholas Gilbo, Ina Jochmans, Mauricio Sainz-Barriga, et al.
Acta Clinica Belgica|August 28, 2018
Thrombosis of a portal vein aneurysm: a case report with literature reviewCharlotte De Vloo, Tom Matton, Wouter Meersseman, et al.
The American Journal of Pathology|January 17, 2015
The FXR agonist obeticholic acid prevents gut barrier dysfunction and bacterial translocation in cholestatic ratsLen Verbeke, Ricard Farre, Bert Verbinnen, et al.
Scientific Reports|September 17, 2016
FXR agonist obeticholic acid reduces hepatic inflammation and fibrosis in a rat model of toxic cirrhosisLen Verbeke, Inge Mannaerts, Robert Schierwagen, et al.
Plos One|September 18, 2015
Copeptin as an Indicator of Hemodynamic Derangement and Prognosis in Liver CirrhosisAnnarein J C Kerbert, Len Verbeke, Fang W T Chiang, et al.
Laboratory Investigation; a Journal of Technical Methods and Pathology|August 15, 2012
Increased intrahepatic resistance in severe steatosis: endothelial dysfunction, vasoconstrictor overproduction and altered microvascular architectureSven Francque, Wim Laleman, Len Verbeke, et al.
Pageof 3

Showing results (11-20 of 22) with videos related to

Sort By:
Pageof 3
Expert Review of Gastroenterology & Hepatology|July 26, 2011
Acute-on-chronic liver failure: current concepts on definition, pathogenesis, clinical manifestations and potential therapeutic interventionsWim Laleman, Len Verbeke, Philippe Meersseman, et al.
Endoscopy|November 25, 2017
The economic impact of using single-operator cholangioscopy for the treatment of difficult bile duct stones and diagnosis of indeterminate bile duct stricturesPierre H Deprez, Rodrigo Garces Duran, Tom Moreels, et al.
Hepatology (Baltimore, Md.)|November 22, 2013
Obeticholic acid, a farnesoid X receptor agonist, improves portal hypertension by two distinct pathways in cirrhotic ratsLen Verbeke, Ricard Farre, Jonel Trebicka, et al.
Plos One|January 7, 2017
Farnesoid X Receptor Activation Attenuates Intestinal Ischemia Reperfusion Injury in RatsLaurens J Ceulemans, Len Verbeke, Jean-Paul Decuypere, et al.
Transplantation Direct|April 18, 2019
Age Matching of Elderly Liver Grafts With Elderly Recipients Does Not Have a Synergistic Effect on Long-term Outcomes When Both Are Carefully SelectedNicholas Gilbo, Ina Jochmans, Mauricio Sainz-Barriga, et al.
Acta Clinica Belgica|August 28, 2018
Thrombosis of a portal vein aneurysm: a case report with literature reviewCharlotte De Vloo, Tom Matton, Wouter Meersseman, et al.
The American Journal of Pathology|January 17, 2015
The FXR agonist obeticholic acid prevents gut barrier dysfunction and bacterial translocation in cholestatic ratsLen Verbeke, Ricard Farre, Bert Verbinnen, et al.
Scientific Reports|September 17, 2016
FXR agonist obeticholic acid reduces hepatic inflammation and fibrosis in a rat model of toxic cirrhosisLen Verbeke, Inge Mannaerts, Robert Schierwagen, et al.
Plos One|September 18, 2015
Copeptin as an Indicator of Hemodynamic Derangement and Prognosis in Liver CirrhosisAnnarein J C Kerbert, Len Verbeke, Fang W T Chiang, et al.
Laboratory Investigation; a Journal of Technical Methods and Pathology|August 15, 2012
Increased intrahepatic resistance in severe steatosis: endothelial dysfunction, vasoconstrictor overproduction and altered microvascular architectureSven Francque, Wim Laleman, Len Verbeke, et al.
Pageof 3